<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03994731</url>
  </required_header>
  <id_info>
    <org_study_id>HZNP-KRY-202</org_study_id>
    <nct_id>NCT03994731</nct_id>
  </id_info>
  <brief_title>Study of KRYSTEXXA® (Pegloticase) Plus Methotrexate in Patients With Uncontrolled Gout</brief_title>
  <acronym>MIRROR RCT</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled GOut Receiving KRYSTEXXA® (Pegloticase) (MIRROR Randomized Controlled Trial [RCT])</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Horizon Therapeutics Ireland DAC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Horizon Pharma Ireland, Ltd., Dublin Ireland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Approximately 135 participants will be randomized. Study duration will be approximately 86
      weeks.

      The purpose of this study is to assess the potential for pegloticase with methotrexate (MTX)
      to increase the response rate seen with pegloticase alone, and to characterize the safety,
      tolerability and pharmacokinetics (PK) of the concomitant use of pegloticase with MTX, by
      comparing pegloticase co-administered with MTX to pegloticase co-administered with placebo
      for MTX in adults with uncontrolled gout.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a Phase 4, multicenter, randomized, double-blind, placebo-controlled,
      parallel-group, efficacy and safety study of pegloticase with MTX vs. pegloticase with
      placebo for MTX in adult participants with uncontrolled gout.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 13, 2019</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Serum Uric Acid Responders (sUA &lt; 6 mg/dL) during Month 6</measure>
    <time_frame>Month 6</time_frame>
    <description>Serum uric acid (sUA) responders defined as participants achieving and maintaining sUA &lt;6 mg/dL for at least 80% of the time during Month 6 (Weeks 20, 21, 22, 23 and 24)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Serum Uric Acid Responders (sUA &lt; 6 mg/dL) during Month 9</measure>
    <time_frame>Month 9</time_frame>
    <description>Serum uric acid (sUA) responders defined as participants achieving and maintaining sUA &lt;6 mg/dL for at least 80% of the time during Month 9 (Weeks 32, 34 and 36)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Serum Uric Acid Responders (sUA &lt; 6 mg/dL) during Month 12</measure>
    <time_frame>Month 12</time_frame>
    <description>Serum uric acid (sUA) responders defined as participants achieving and maintaining sUA &lt;6 mg/dL for at least 80% of the time during Month 12 (Weeks 48, 50 and 52)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with complete resolution of ≥ 1 tophi at Week 52</measure>
    <time_frame>Week 52</time_frame>
    <description>proportion of participants with complete resolution of ≥ 1 tophi (using digital photography) at Week 52 in subjects with tophi at baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">135</enrollment>
  <condition>Gout</condition>
  <arm_group>
    <arm_group_label>Pegloticase with methotrexate (MTX)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive MTX (15 mg) (weekly) during the Tolerability Assessment Period and Run-in Period, then pegloticase (every 2 weeks) with MTX (weekly) for 52 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pegloticase with placebo for methotrexate (MTX)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive MTX (15 mg) (weekly) during the Tolerability Assessment Period, placebo for MTX (weekly) in the Run-in Period, then pegloticase (every 2 weeks) with placebo for MTX (weekly) for 52 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pegloticase with MTX</intervention_name>
    <description>Participants will receive MTX during the Tolerability Assessment Period then MTX during the run-in period then pegloticase with MTX for 52 weeks</description>
    <arm_group_label>Pegloticase with methotrexate (MTX)</arm_group_label>
    <other_name>methotrexate (MTX)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pegloticase with placebo for MTX</intervention_name>
    <description>Participants will receive MTX during the Tolerability Assessment Period then placebo for MTX during the run-in period then pegloticase with placebo for MTX for 52 weeks</description>
    <arm_group_label>Pegloticase with placebo for methotrexate (MTX)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Willing and able to give informed consent.

          2. Willing and able to comply with the prescribed treatment protocol and evaluations for
             the duration of the study.

          3. Adult men or women ≥18 years of age.

          4. Uncontrolled gout, defined as meeting the following criteria:

               -  Hyperuricemia during the screening period defined as sUA ≥7 mg/dL, and;

               -  Failure to maintain normalization of sUA with xanthine oxidase inhibitors at the
                  maximum medically appropriate dose, or with a contraindication to xanthine
                  oxidase inhibitor therapy based on medical record review or subject interview,
                  and;

               -  Symptoms of gout including at least 1 of the following:

                    -  Presence of at least one tophus

                    -  Recurrent flares defined as 2 or more flares in the past 12 months prior to
                       screening

                    -  Presence of chronic gouty arthritis

          5. Willing to discontinue any oral urate lowering therapy for at least 7 days prior to
             MTX dosing at Week -6 and remain off when receiving pegloticase infusions.

          6. Women of childbearing potential (including those with an onset of menopause &lt;2 years
             prior to screening, non-therapy-induced amenorrhea for &lt;12 months prior to screening,
             or not surgically sterile [absence of ovaries and/or uterus]) must have negative
             serum/urine pregnancy tests during Screening and Week -6; subjects must agree to use 2
             reliable forms of contraception during the study, one of which is recommended to be
             hormonal, such as an oral contraceptive. Hormonal contraception must be started ≥1
             full cycle prior to Week -6 (start of MTX) and continue for 30 days after the last
             dose of pegloticase, or at least one ovulatory cycle after the last dose of MTX or
             placebo for MTX (whichever is the longest duration after the last dose of pegloticase
             or MTX or placebo for MTX). Highly effective contraceptive methods (with a failure
             rate &lt;1% per year), when used consistently and correctly, include implants,
             injectables, combined oral contraceptives, some intrauterine devices, sexual
             abstinence, or vasectomized partner.

          7. Men who are not vasectomized must agree to use appropriate contraception so as to not
             impregnate a female partner of reproductive potential during the study, beginning with
             the initiation of MTX at Week -6 and continuing and for at least 3 months after the
             last dose of MTX or placebo for MTX.

          8. Able to tolerate MTX 15 mg orally for 2 weeks (Week -6 through Week -4) prior to
             randomization.

        Exclusion Criteria:

          1. Weight &gt;160 kg (352 pounds) at Screening.

          2. Any serious acute bacterial infection, unless treated and completely resolved with
             antibiotics at least 2 weeks prior to the Week -6 Visit.

          3. Severe chronic or recurrent bacterial infections, such as recurrent pneumonia or
             chronic bronchiectasis.

          4. Current or chronic treatment with systemic immunosuppressive agents such as MTX,
             azathioprine, or mycophenolate mofetil; prednisone ≥10 mg/day or equivalent dose of
             other corticosteroid on a chronic basis (3 months or longer) would also meet exclusion
             criteria.

          5. History of any transplant surgery requiring maintenance immunosuppressive therapy.

          6. Known history of hepatitis B virus surface antigen positivity or hepatitis B DNA
             positivity.

          7. Known history of hepatitis C virus RNA positivity.

          8. Known history of Human Immunodeficiency Virus (HIV) positivity.

          9. Glucose-6-phosphate dehydrogenase deficiency (tested at the Screening Visit).

         10. Chronic renal impairment defined as estimated glomerular filtration rate (eGFR) &lt;40
             mL/min/1.73 m2 or currently on dialysis.

         11. Non-compensated congestive heart failure or hospitalization for congestive heart
             failure within 3 months of the Screening Visit, uncontrolled arrhythmia, treatment for
             acute coronary syndrome (myocardial infarction or unstable angina), or uncontrolled
             blood pressure (&gt;160/100 mmHg) prior to Randomization at Week -4.

         12. Pregnant, planning to become pregnant, breastfeeding, planning to impregnate female
             partner, or not on an effective form of birth control, as determined by the
             Investigator.

         13. Prior treatment with pegloticase, another recombinant uricase (rasburicase), or
             concomitant therapy with a polyethylene glycol-conjugated drug.

         14. Known allergy to pegylated products or history of anaphylactic reaction to a
             recombinant protein or porcine product.

         15. Contraindication to MTX treatment or MTX treatment considered inappropriate.

         16. Known intolerance to MTX.

         17. Receipt of an investigational drug within 4 weeks or 5 half-lives, whichever is
             longer, prior to MTX administration at Week -6 or plans to take an investigational
             drug during the study.

         18. Liver transaminase levels (AST or ALT) &gt; upper limit of normal (ULN) or albumin &lt; the
             lower limit of normal (LLN) at the Screening Visit).

         19. Chronic liver disease.

         20. White blood cell count &lt; 4,000/ul, hematocrit &lt; 32 percent, or platelet count
             &lt;75,000/ul.

         21. Currently receiving systemic or radiologic treatment for ongoing cancer.

         22. History of malignancy within 5 years other than non-melanoma skin cancer or in situ
             carcinoma of cervix.

         23. Diagnosis of osteomyelitis.

         24. Known history of hypoxanthine-guanine phosphoribosyl-transferase deficiency, such as
             Lesch-Nyhan and Kelley-Seegmiller syndrome.

         25. Unsuitable candidate for the study, based on the opinion of the Investigator (e.g.,
             cognitive impairment), such that participation might create undue risk to the subject
             or interfere with the subject's ability to comply with the protocol requirements or
             complete the study.

         26. Alcohol use in excess of 3 alcoholic beverages per week.

         27. A known intolerance to all protocol standard gout flare prophylaxis regimens (i.e.
             subject must be able to tolerate at least one: colchicine and/or non-steroidal anti
             inflammatory drugs and/or low dose prednisone ≤10 mg/day).

         28. Current pulmonary fibrosis, bronchiectasis or interstitial pneumonitis. If deemed
             necessary by the Investigator, a chest X-ray may be performed during Screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Colleen Canavan, BS</last_name>
    <role>Study Director</role>
    <affiliation>Horizon Pharma Rheumatology LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Colleen Canavan, BS</last_name>
    <phone>866-479-6742</phone>
    <email>clinicaltrials@horizontherapeutics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Molly Weiss, BA</last_name>
    <phone>866-479-6742</phone>
    <email>clinicaltrials@horizontherapeutics.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Biggers</last_name>
      <phone>205-934-1444</phone>
      <email>sbiggers@uabmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Orthopedic Physicians Alaska</name>
      <address>
        <city>Anchorage</city>
        <state>Alaska</state>
        <zip>99508</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Campione</last_name>
      <phone>907-341-5220</phone>
      <email>acampione@opaak.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arizona Arthritis and Rheumatology Research, PLLC - Flagstaff</name>
      <address>
        <city>Flagstaff</city>
        <state>Arizona</state>
        <zip>86001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edgar Leon</last_name>
      <phone>480-321-8581</phone>
      <email>edgar.leon@azarthritis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arizona Arthritis and Rheumatology Research, PLLC-West</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85306</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gloria Santimaw</last_name>
      <phone>602-386-4970</phone>
      <email>gloria.santimaw@azarthritis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arizona Arthritis and Rheumatology Research, PLLC-East</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina O'hearn</last_name>
      <phone>480-321-8558</phone>
      <email>christina.ohearn@azarthritis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Applied Research Center of Arkansas, Inc</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rhonda Rowton</last_name>
      <phone>501-954-7822</phone>
      <email>rhonda@arcarkansas.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>TriWest Research Associates</name>
      <address>
        <city>El Cajon</city>
        <state>California</state>
        <zip>92020</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lizenia Hernandez</last_name>
      <phone>619-334-4735</phone>
      <email>lhernandez@triwestresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Advanced Investigative Medicine, Inc.</name>
      <address>
        <city>Hawthorne</city>
        <state>California</state>
        <zip>90250</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Yousef</last_name>
      <phone>424-245-5682</phone>
      <email>dyousef@aimclinicalresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Axis Clinical Trials</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elianet De La Cruz</last_name>
      <phone>310-289-8242</phone>
      <email>eli@axistoday.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ACRC Studies</name>
      <address>
        <city>Poway</city>
        <state>California</state>
        <zip>92064</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leo Cortez</last_name>
      <email>leo@acrcstudies.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ClinEdge Sierra Rheumatology, Inc.</name>
      <address>
        <city>Roseville</city>
        <state>California</state>
        <zip>95661</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gaby Zumaran</last_name>
      <phone>916-966-7452</phone>
      <email>gabyzumaran@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>East Bay Rheumatology Medical Group, Inc.</name>
      <address>
        <city>San Leandro</city>
        <state>California</state>
        <zip>94578</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacquelene Catap</last_name>
      <phone>510-357-1040</phone>
      <email>jcatap@ebrri.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medvin Clinical Research</name>
      <address>
        <city>Tujunga</city>
        <state>California</state>
        <zip>91042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mayra Francisco</last_name>
      <phone>213-281-5146</phone>
      <email>mayra@medvinresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>San Fernando Valley Health Institute</name>
      <address>
        <city>Van Nuys</city>
        <state>California</state>
        <zip>91405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edith Sisneros</last_name>
      <phone>818-222-6862</phone>
      <email>edith@sanfernandohealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ventura Clinical Trials</name>
      <address>
        <city>Ventura</city>
        <state>California</state>
        <zip>93003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Iliana Rojas</last_name>
      <phone>805-339-0549</phone>
      <email>irojas@venturaclinicaltrials.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Colorado Division of Rheumatology</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chong Pedrick</last_name>
      <email>chong.pedrick@CUAnschutz.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Denver Arthritis Clinic</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Theresa Hernandez</last_name>
      <phone>303-394-2828</phone>
      <phone_ext>177</phone_ext>
      <email>thernandez@dacdenver.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Avail Clinical Research</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Dittman</last_name>
      <phone>386-785-2400</phone>
      <email>jdittman@accelclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prohealth Research Center</name>
      <address>
        <city>Doral</city>
        <state>Florida</state>
        <zip>33166</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magda Hernandez</last_name>
      <phone>305-960-7934</phone>
      <email>mhernandez@prohresearchcenter.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Omega Research Maitland</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32808</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danielle Cortese</last_name>
      <phone>407-988-1075</phone>
      <email>dcortese@omegarcllc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>DMI Research</name>
      <address>
        <city>Pinellas Park</city>
        <state>Florida</state>
        <zip>33782</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Schiara Kitwood</last_name>
      <phone>727-531-2848</phone>
      <phone_ext>104</phone_ext>
      <email>skitwood@dmiresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Napa Research Center</name>
      <address>
        <city>Pompano Beach</city>
        <state>Florida</state>
        <zip>33064</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magda Hernandez</last_name>
      <phone>305-960-7934</phone>
      <email>mhernandez@prohresearchcenter.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>GCP Clinical Research</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marlene Klingeman</last_name>
      <phone>321-315-0780</phone>
      <email>marlenek@gcpclinicalresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Florida Medical Clinic, LLC</name>
      <address>
        <city>Zephyrhills</city>
        <state>Florida</state>
        <zip>33542</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandi Ellis</last_name>
      <phone>813-780-8368</phone>
      <email>sellis@floridamedicalclinic.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Luke's Clinic - Rheumatology</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelli Bruni</last_name>
      <phone>208-706-9081</phone>
      <email>brunik@slhs.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MD Medical Research</name>
      <address>
        <city>Oxon Hill</city>
        <state>Maryland</state>
        <zip>20745</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie Edwards</last_name>
      <phone>301-329-2608</phone>
      <email>marie.edwards@mdmedicalresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Center for Rheumatology and Bone Research</name>
      <address>
        <city>Wheaton</city>
        <state>Maryland</state>
        <zip>20902</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan Lormore</last_name>
      <phone>301-942-6610</phone>
      <email>mlormore@arapc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Infusion Associates</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49525</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Beth Readwin</last_name>
      <email>mary.readwin@infusionassociates.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute of Michigan, LLC</name>
      <address>
        <city>Saint Clair Shores</city>
        <state>Michigan</state>
        <zip>48081</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Dennis</last_name>
      <phone>586-777-7577</phone>
      <email>sdennis@researchmi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Benefis Hospital</name>
      <address>
        <city>Great Falls</city>
        <state>Montana</state>
        <zip>59405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kerstin Leighland</last_name>
      <phone>406-454-2171</phone>
      <email>KerstinLeigland@benefis.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Santa Fe Rheumatology</name>
      <address>
        <city>Santa Fe</city>
        <state>New Mexico</state>
        <zip>87505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colin Camp</last_name>
      <phone>608-855-9124</phone>
      <email>ccamp@interspond.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Long Island Arthritis &amp; Osteoporosis Care</name>
      <address>
        <city>Babylon</city>
        <state>New York</state>
        <zip>11702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Polly Elkins</last_name>
      <phone>631-376-4800</phone>
      <email>pollya.elkins@outlook.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Buffalo Rheumatology and Medicine</name>
      <address>
        <city>Orchard Park</city>
        <state>New York</state>
        <zip>14127</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Dorsheimer</last_name>
      <phone>716-675-2500</phone>
      <phone_ext>251</phone_ext>
      <email>adorsheimer@buffalorheumatology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>NorthEast Rheumatology/Atrium Health</name>
      <address>
        <city>Concord</city>
        <state>North Carolina</state>
        <zip>28025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Steen</last_name>
      <email>susan.steen@atriumhealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medication Management, LLC</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27408</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Makeanly Gary</last_name>
      <phone>608-855-9124</phone>
      <email>makeanly.gary@emailmm.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ClinEdge PMG Research of Hickory, LLC</name>
      <address>
        <city>Hickory</city>
        <state>North Carolina</state>
        <zip>28602</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Everhart</last_name>
      <phone>828-345-5060</phone>
      <email>nicole.everhart@pmg-research.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ClinEdge PMG Research of Salisbury, LLC</name>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <zip>28144</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacy Smith</last_name>
      <phone>704-647-9913</phone>
      <email>stacy.smith@pmg-research.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shelby Clinical Research, LLC</name>
      <address>
        <city>Shelby</city>
        <state>North Carolina</state>
        <zip>28150</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pamela Seagle</last_name>
      <phone>980-552-9230</phone>
      <email>pseagle@shelbyclinicalresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>PMG Research of Wilmington, LLC</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chandler Allely</last_name>
      <phone>910-623-9041</phone>
      <email>chandler.allely@pmg-research.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Premier Clinical/STAT Research</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45417</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Derek Tipton</last_name>
      <phone>937-223-4229</phone>
      <email>derek@statreserach.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Paramount Medical Research &amp; Consulting, LLC</name>
      <address>
        <city>Middleburg Heights</city>
        <state>Ohio</state>
        <zip>44130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erika Hannigan</last_name>
      <phone>440-826-0742</phone>
      <email>ehanniganpmr15@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Research Source Inc.</name>
      <address>
        <city>Perrysburg</city>
        <state>Ohio</state>
        <zip>43551</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denise Coressel</last_name>
      <phone>419-873-1532</phone>
      <email>dcoressel@sbcglobal.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Premeir Clinical/STAT Research - Springboro</name>
      <address>
        <city>Springboro</city>
        <state>Ohio</state>
        <zip>45066</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Derek Tipton</last_name>
      <phone>937-223-4229</phone>
      <email>derek@statresearch.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Altoona Center for Clinical Research</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krista Perrin</last_name>
      <phone>814-693-0300</phone>
      <phone_ext>146</phone_ext>
      <email>kristaperrin@altoonaresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Piedmont Arthritis Clinic</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Williams</last_name>
      <phone>864-527-2307</phone>
      <email>kim.williams@innovativeclinicalresearch.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Articularis Healthcare Group</name>
      <address>
        <city>Summerville</city>
        <state>South Carolina</state>
        <zip>29486</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Soua Xiong</last_name>
      <phone>843-572-1818</phone>
      <email>sxiong@articularishealthcare.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>West Tennessee Research Institute</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sherry Wiggins</last_name>
      <phone>731-633-0045</phone>
      <email>sharvill@arthritisclinic.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ramesh C. Gupta, M.D.</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manju Gupta</last_name>
      <phone>901-681-9670</phone>
      <email>smartmanju@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Diagnostic and Interventional Nephrology Of Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debra Garza</last_name>
      <phone>832-682-8243</phone>
      <email>DGarza@diagnosticclinic.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Consultants - Frostwood</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roxanne McIntosh</last_name>
      <phone>713-932-0054</phone>
      <email>mailto:roxanne@clinicalrc.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Consultants - Astoria</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77089</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arman Hossain</last_name>
      <phone>281-944-3620</phone>
      <email>arman@clinicalrc.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arthritis Clinic of Central Texas</name>
      <address>
        <city>San Marcos</city>
        <state>Texas</state>
        <zip>78666</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Kelly</last_name>
      <phone>512-667-7123</phone>
      <phone_ext>230</phone_ext>
      <email>mkelly.acct@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arthritis &amp; Osteoporosis Clinic - Waco</name>
      <address>
        <city>Waco</city>
        <state>Texas</state>
        <zip>76710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Vela</last_name>
      <phone>254-755-4582</phone>
      <phone_ext>1866</phone_ext>
      <email>kvela2716@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Western Washington Arthritis Clinic</name>
      <address>
        <city>Bothell</city>
        <state>Washington</state>
        <zip>98021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Bruggman</last_name>
      <phone>425-248-2635</phone>
      <email>nbruggman@wwmedgroup.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arthritis Northwest</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terri Cone</last_name>
      <phone>509-838-6500</phone>
      <phone_ext>310</phone_ext>
      <email>tcone@arthritisnw.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rheumatic Disease Center</name>
      <address>
        <city>Glendale</city>
        <state>Wisconsin</state>
        <zip>53219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lynn Kritter</last_name>
      <phone>414-351-4009</phone>
      <email>lynn.kritter@rdcwi.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>June 19, 2019</study_first_submitted>
  <study_first_submitted_qc>June 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2019</study_first_posted>
  <last_update_submitted>May 11, 2020</last_update_submitted>
  <last_update_submitted_qc>May 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>gout</keyword>
  <keyword>uncontrolled gout</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gout</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

